Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAVZEJ)

Drug Name
PD156707 Drug Info
Synonyms
PD-156707; 162412-70-6; CHEMBL25438; GTPL999; DTXSID80635455; HMS3263B04; Tox21_501201; CCG-222505; NCGC00261886-01; LS-34623; P-305; PD-156707, > Sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate.; Sodium (2Z)-2-(2H-1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate; sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate
Cross-matching ID
PubChem CID
23670447
CAS Number
CAS 162412-70-6
TTD Drug ID
DMAVZEJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Endothelin A receptor (EDNRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [2]
Ambrisentan DMD1QXW Pulmonary arterial hypertension BB01.0 Approved [3]
Macitentan DMP79A1 Cardiovascular disease BA00-BE2Z Approved [4]
Sparsentan DMMP51W IgA nephropathy MF8Y Approved [5]
LU302146 DMMJVXZ Pulmonary hypertension BB01 Approved [6]
Atrasentan DMM74PK Diabetic nephropathy GB61.Z Phase 3 [7]
Clazosentan DMQSBX4 Cerebral vasospasm BA85.Z Phase 3 [8]
PF-1228305 DMS1EQ7 Pulmonary hypertension BB01 Phase 3 [9]
Darusentan DMN8DQH Hypotension BA20-BA21 Phase 3 [10]
BQ-123 DM0MO8I Pulmonary arterial hypertension BB01.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endothelin A receptor (EDNRA) TTKRD0G EDNRA_HUMAN Antagonist [1]

References

1 Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Pharm Biotechnol. 1998;11:81-112.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
5 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
6 Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
7 Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
8 Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
9 Pfizer. Product Development Pipeline. March 31 2009.
10 Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
11 Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.